Cardiovascular Toxicities of CAR T-cell Therapy

Nikita P. Patel, Peter G. Doukas, Leo I. Gordon, Nausheen Akhter*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of review: This review provides a contemporary overview of current studies outlining the incidence and characteristics of CAR T-cell cardiotoxicity in an effort to identify future directions for research and potential opportunities for prevention and intervention. Recent Findings: Cardiovascular events occurred in anywhere between 10 and 36% of patients in CAR T-cell clinical trials, ranging from tachycardia, hypotension, arrhythmia, decreased left ventricular systolic function to cardiogenic shock and death. Cardiac events are more often associated higher grades (> 2) of cytokine release syndrome and frequently proceeded by an elevated troponin. Summary: There is a growing recognition of cardiotoxicities of CAR T-cell therapy but has a limited study in this area. The mechanism of left ventricular dysfunction due to CAR T-cell therapy is also unknown. As CAR T-cell use expands, it becomes imperative to truly understand the mechanism behind cardiac injury and to assess long-term follow-up data as this will allow for surveillance, early intervention, and potentially prevention of cardiotoxicity.

Original languageEnglish (US)
Article number78
JournalCurrent oncology reports
Volume23
Issue number7
DOIs
StatePublished - Jul 2021

Keywords

  • CAR T-cell
  • Cardio-oncology
  • Cardiotoxicity
  • Chimeric antigen receptor
  • Cytokine release syndrome

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Cardiovascular Toxicities of CAR T-cell Therapy'. Together they form a unique fingerprint.

Cite this